A377740 Stock Overview
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
BioNote, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,065.00 |
| 52 Week High | ₩6,460.00 |
| 52 Week Low | ₩3,800.00 |
| Beta | 0 |
| 1 Month Change | -9.87% |
| 3 Month Change | -3.33% |
| 1 Year Change | -34.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| A377740 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.5% | 5.4% | 3.4% |
| 1Y | -35.0% | 6.7% | 7.1% |
Return vs Industry: A377740 underperformed the KR Biotechs industry which returned 6.7% over the past year.
Return vs Market: A377740 underperformed the KR Market which returned 7.1% over the past year.
Price Volatility
| A377740 volatility | |
|---|---|
| A377740 Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A377740 has not had significant price volatility in the past 3 months.
Volatility Over Time: A377740's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | n/a | www.bionote.co.kr |
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents.
BioNote, Inc. Fundamentals Summary
| A377740 fundamental statistics | |
|---|---|
| Market cap | ₩414.86b |
| Earnings (TTM) | -₩20.50b |
| Revenue (TTM) | ₩90.08b |
4.6x
P/S Ratio-20.2x
P/E RatioIs A377740 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A377740 income statement (TTM) | |
|---|---|
| Revenue | ₩90.08b |
| Cost of Revenue | ₩101.74b |
| Gross Profit | -₩11.66b |
| Other Expenses | ₩8.84b |
| Earnings | -₩20.50b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -200.84 |
| Gross Margin | -12.94% |
| Net Profit Margin | -22.75% |
| Debt/Equity Ratio | 0% |
How did A377740 perform over the long term?
See historical performance and comparison